- No public price.
- Attested
- Type II
- 3
- —
Decision support
PaceMate
by PaceMate
Cardiac device remote monitoring platform whose Auto-Triage ranks device alerts by clinical priority for device clinics.
On this page
47/100
Editorial rating 3.5 / 5
- Regulatory & Compliance10/22
HIPAA + (SOC2 or BAA) attested
- Clinical Integration6.5/11.6
Epic + Oracle Cerner + Athena
- Evidence Strength19.2/30
3 peer-reviewed papers
- Vendor & Market3/18
Seed-stage or unfunded
- Sentiment & Transparency1.3/2.5
Pricing on request, no public amounts
▸ Show all 11 dimensions▾ Hide dimension detail
- FDA clearance0/12
No FDA clearance listed
- HIPAA / SOC2 / BAA10/10
HIPAA + (SOC2 or BAA) attested
- EHR integrations (count)2/6
3 EHR integrations
- Top-3 EHR coverage (Epic / Oracle / Athena)5/5
Epic + Oracle Cerner + Athena
- Bidirectional write-back0/1
No bidirectional write-back documented
- Peer-reviewed papers15/21
3 peer-reviewed papers
- RCT / meta-analysis / systematic review5/9
1 observational study (no RCT)
- Funding & adoption signal3/12
Seed-stage or unfunded
- Years in market0/6
Founded year not recorded
- Pricing transparency1/3
Pricing on request, no public amounts
Cardiac device remote monitoring platform whose Auto-Triage ranks device alerts by clinical priority for device clinics.
No public price. HIPAA + SOC 2 Type II attested. integrates with Epic, Oracle Health, athenahealth.
Evidence record
No FDA decision cited in our research as of November 2, 2026.
3 studies on PubMed: 2 other, 1 observational, published 2023 to 2026. Read the literature summary
- Score computed November 2, 2026, method 1.2.0
- Review written November 2, 2026
MedAI Verdict, PaceMate record, https://medaiverdict.com/tools/pacemate, version November 2, 2026
Bottom line
PaceMate's Auto-Triage ranks alerts from implanted cardiac devices by clinical priority. The vendor calls it "a proprietary algorithmic intelligence engine" and says "AI informs the decision. The clinician makes it." It sits inside PaceMateLIVE, which lists bidirectional links to Epic, Oracle Health and athenahealth. The efficacy figures are the vendor's own, 61% less physician alert burden and 73% fewer loop recorder false positives. A clinic that wants a paper on the triage logic itself should look elsewhere, because none of the PaceMate-affiliated papers is verified to evaluate the product.
What do Auto-Triage and Auto-Script do?
Auto-Triage has customizable alert parameters, and the vendor says device alerts are enriched with EHR data. Auto-Script, which the vendor says uses "advanced algorithms to write a preliminary report", targets documentation for CPT 93294 to 93298, with a claimed 70% cut in documentation time.
The platform lists PaceMateLIVE software, ambulatory monitoring, remote services, a patient portal, a Data and Analytics module and PaceArt Optima for cardiac data management. The vendor describes itself as "The Only Enterprise-Ready Cardiac Data Platform". Two case-study figures, 270 hours saved and 2,100 hours saved annually, come with no methodology. The vendor also reports 75% average billing capture within 90 days and 543 hours saved annually at Ascension Jacksonville.
What do the ten affiliated papers cover?
PubMed lists ten PaceMate-affiliated papers, and none has the product in its title. Four are on topic: a 2021 analysis of remote monitoring alert burden in more than 26,000 patients (PMID 33602404), a 2021 study of false-positive alerts from implantable loop recorders (PMID 34708660), a 2025 Heart Rhythm paper on AI algorithms to reduce loop recorder transmissions (PMID 39427689) and a 2024 Heart Rhythm O2 perspective from the Heart Rhythm Society on CIED remote monitoring workflows (PMID 39803615). Whether PaceMate was used in them is not verified. The vendor claims 39 peer-reviewed studies.
Who is behind it?
The site states no headquarters, legal entity or founding year. JR Finkelmeier is CEO, Chandler Yoquelet is president and CFO, Gabe Rosu is CTO and co-founder, and Dr. Benjamin Steinberg is chief medical officer. The board includes representatives of Generator Ventures, Lead Edge Capital and Ballast Point Ventures, and no funding round is disclosed. A webinar titled "The PaceArt Acquisition Explained" is linked from the site, with no parties or terms given. The vendor claims 2.3 million patients managed and EHR integrations across "700+ health systems and practices".
What does it connect to, and what does it hold?
The vendor says Epic (bidirectional, SMART on FHIR), Oracle Health (bidirectional) and athenahealth (bidirectional, FHIR API) are connected. It reports 14 OEM-integrated device manufacturers and names Medtronic SessionSync.
The vendor's security page lists ISO/IEC 27001:2022 audited by A-LIGN, HITRUST r2, SOC 2 Type 2, SOC 3 and HIPAA with a BAA available, hosted on AWS.
PaceMate makes no FDA statement about Auto-Triage or Auto-Script. The only openFDA 510(k) record carrying the name is K900317 from 1990, a thermal dilution catheter from an unrelated company.
Four tiers, no prices
The pricing page shows Software ("For clinics that want to do it themselves"), Flexible, Premium (marked "Popular") and Elite, without amounts, a trial or refund terms.
The verdict
Device clinics on Epic, Oracle Health or athenahealth are the ones the integration list covers. The Auto-Triage and Auto-Script numbers are PaceMate's own, and the on-topic papers are by affiliated authors.
Editorial review last generated November 2, 2026. Synthesized from clinician sentiment, peer-reviewed coverage, and our editorial silo picks. Refined by hand where vendor facts change.
What it costs
All tiers are custom-quoted. The vendor does not publish per-provider list pricing.
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | Not stated | Not stated | No public price. |
Source: vendor pricing page. Last checked November 2, 2026.
What deploys cleanly
Carries ISO 27001, HITRUST r2, SOC 2 Type II, SOC 3, HIPAA per vendor documentation. Independent attestation review is the buyer's responsibility before clinical deployment. Integrates with 3 EHRs: Epic, Oracle Health, athenahealth.
What the literature says
3 peer-reviewed studies indexed on PubMed evaluate PaceMate in clinical contexts. The most relevant are shown below, ranked by editorial relevance score combining title match, study design, recency, and journal tier.
- Variability in implantable cardioverter-defibrillator battery longevity. (opens in new tab)
- Freeman JV, Torre M, Sanders P, et al.· Heart Rhythm· 2026
- Implantable cardioverter-defibrillator (ICD) battery longevity impacts the need for generator replacement, with the accompanying risk of complications and cost. We sought to identify factors associated with ICD battery longevity and compare manufacturers. We used a nationwide, multicenter remote monitoring dataset (PaceMate) to evaluate ICDs implanted between 2003 and 2023, assessing time from implant to replacement interval (RI). We compared Kaplan-Meier survival curves and device parameters across manufacturers. We evaluated observed vs manufacturer-estimated battery longevity in devices th…
- Variability in Pacemaker Battery Estimates and Performance. (opens in new tab)
- Steinberg BA, Gillette R, Torre M, et al.· Pacing Clin Electrophysiol· 2026
- Permanent pacemaker (PPM) battery longevity impacts downstream procedures, patient outcomes, and healthcare costs. To measure and predict PPM battery longevity in routine, clinical practice. We analyzed a nationwide, multicenter, remote monitoring dataset (PaceMate) to evaluate PPM battery longevity from 2007 to 2023. Multivariable models identified factors associated with replacement interval (RI) across device types and manufacturers. We also compared observed versus expected battery longevity and assessed differences between newer and older generation pacemakers. We included 58,395 devices…
- Atrial fibrillation detection using insertable cardiac monitor after stroke: A real-world cohort study. (opens in new tab)
- Noubiap JJ, Thomas G, Middeldorp ME, et al.· J Cardiovasc Electrophysiol· 2023
- This study aimed to report the real-world atrial fibrillation (AF) diagnostic yield of the implantable cardiac monitor (ICM) in patients with stroke or transient ischemic attack (TIA), and compare it to patients with an ICM for unexplained syncope. We used patient data from device clinics across the United States of America with ICM remote monitoring via PaceMate™, implanted for stroke or TIA, and unexplained syncope. Patients with known AF or atrial flutter were excluded. The outcome was AF lasting ≥2 min, adjudicated by International Board of Heart Rhythm Examiners…
Other decision support
See the full decision support rankingUpToDate Expert AI
by Wolters Kluwer
Generative AI version of UpToDate that answers only from UpToDate's expert-authored library. Included in UpToDate subscriptions in the US.
July 2026 figure from a third-party price comparison; the vendor page shows no amount. Wolters Kluwer states Expert AI is included in all UpToDate subscriptions in the US. Trainees $219 per year with proof.
OpenEvidence
by OpenEvidence
Free physician-only literature-grounded Q&A, 1M consults/day.
Free for NPI-verified physicians (ad-funded).
Doximity Ask
by Doximity
Free clinical AI assistant for verified US clinicians, built on Pathway's technology.
Free for verified US clinicians, funded by advertising, per third-party summaries. Doximity's pages returned 403 when read. Also part of enterprise contracts with health systems.DynaMed / Dyna AI
by EBSCO Health
Evidence-based clinical reference from EBSCO with Dyna AI, a generative Q&A add-on, and Epic integration.
Individual plan from the EBSCO store.